Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | WDR5 | P61964 | 1/20 | 0.31 |
| ▸ | LDHA | P00338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4886251 | 0.74 | CYP1A2 (0.31) | CYP1A2WDR5 | |
| SCHEMBL4892473 | 0.57 | CYP1A2 (0.32) | CYP1A2WDR5LDHA | |
| SCHEMBL20957575 | 0.57 | ALDH1A1 (0.44) | — | |
| SCHEMBL898994 | 0.56 | CYP1A2 (0.72) | CYP1A2WDR5LDHA | |
| SCHEMBL10792029 | 0.55 | KDM4E (0.48) | CYP1A2 | |
| SCHEMBL8861245 | 0.53 | SELL (0.52) | CYP1A2 | |
| SCHEMBL11662563 | 0.53 | KDM4E (0.48) | CYP1A2 | |
| SCHEMBL29417502 | 0.52 | CYP1A2 (1.00) | CYP1A2WDR5LDHA | |
| SCHEMBL22122 | 0.52 | CYP1A2 (1.00) | CYP1A2WDR5LDHA | |
| SCHEMBL13445966 | 0.51 | CYP1A2 (0.55) | CYP1A2WDR5LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998951-B2 | treating hepatitis C infection; 6-cyclohexyl-2,3-dihydro-5-phenyl-1,4-oxazino[2,3,4-hi]indole-9-carboxylic acid | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-16 | — | — | US | disclosed |
| WO-2008109584-A1 | HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221090-A1 | HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221090-A1 | HCV NS5B Inhibitors | EIF2AK2, HAVCR2, EIF5B | CYP1A2 362/4885WDR5 2086/4885LDHA 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.